Symbol | Exchange | Currency |
|---|
(Reuters) - Proxy adviser Glass Lewis has urged Ziopharm Oncology (NASDAQ:ZIOP) Inc's shareholders to elect all three of investment firm WaterMill Asset Management Corp's proposed...
Citing the 800 active INDs for cell therapy and gene therapy candidates and the expectation that it will be receiving more that 200 INDs each year by 2020, FDA Commission Scott...
Gainers: Sphere 3D (NASDAQ:ANY) +30%. Overstock.com (NASDAQ:OSTK) +22%. CorMedix (NYSEMKT:CRMD) +18%. TSR (NASDAQ:TSRI) +14%. Tenax Therapeutics (NASDAQ:TENX) +12%. Navios...
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced that it has started enrollment in an exploratory phase II study to evaluate defibrotide for the prevention of CAR T-cell...
The oncology industry is a massive and growing one. In fact, with estimates suggesting that oncology drugs will generate $120 billion in revenue annually over the next few years,...
Eidos Therapeutics, Inc. (EIDX)EIDX bounced 2.41, or 7%, to 36.07, on 85,997 shares traded on Wednesday. It started the day out with a small pop to 33.98, pulled back to the low...
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 8.13 | 8.32 | 8.04 | -0.04 | -0.49% | 7.01M | NYSE | |||
| 1.09 | 1.12 | 1.065 | 0.0000 | 0.00% | 9.44M | NYSE | |||
| 37.51 | 37.67 | 36.25 | +1.17 | +3.22% | 8.44M | NYSE | |||
| 0.1727 | 0.185 | 0.1668 | -0.0056 | -3.14% | 2.30M | NYSE | |||
| 47.10 | 48.82 | 46.34 | -0.85 | -1.77% | 54.34K | NASDAQ | |||
| 44.25 | 46.46 | 44.02 | -0.90 | -1.99% | 5.95M | NYSE | |||
| 3.45 | 3.80 | 3.10 | +1.150 | +50.00% | 68.35M | NASDAQ | |||
| 0.0003 | 0.0003 | 0.0003 | 0.0000 | 0.00% | 0.00 | OTC Markets | |||
| 69.79 | 70.24 | 68.56 | +0.48 | +0.69% | 1.89M | NYSE | |||
| 0.0001 | 0.0001 | 0.0001 | 0.0000 | 0.00% | 0.00 | OTC Markets | |||
| 0.00 | 0.00 | 0.00 | 0.00000 | 0.00% | 3.40K | OTC Markets | |||
| 1.02 | 1.03 | 1.02 | -0.04 | -3.30% | 3.49M | OTC Markets | |||
| 0.00 | 0.00 | 0.00 | 0.0000 | 0.00% | 0.00 | OTC Markets | |||
| 0.00 | 0.00 | 0.00 | 0.0 | 0.00% | 0.00 | OTC Markets |